MY110765A - Compositions containing cholesteryl esters of unsaturated fatty acids - Google Patents
Compositions containing cholesteryl esters of unsaturated fatty acidsInfo
- Publication number
- MY110765A MY110765A MYPI94000009A MYPI19940009A MY110765A MY 110765 A MY110765 A MY 110765A MY PI94000009 A MYPI94000009 A MY PI94000009A MY PI19940009 A MYPI19940009 A MY PI19940009A MY 110765 A MY110765 A MY 110765A
- Authority
- MY
- Malaysia
- Prior art keywords
- fatty acids
- compositions containing
- unsaturated fatty
- cholesteryl esters
- containing cholesteryl
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 title 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 abstract 2
- HXQHFNIKBKZGRP-JRVLCRGASA-N 5,9,12-octadecatrienoic acid Chemical compound CCCCC\C=C\C\C=C\CC\C=C\CCCC(O)=O HXQHFNIKBKZGRP-JRVLCRGASA-N 0.000 abstract 1
- -1 CHOLESTEROL FATTY ACID ESTER Chemical class 0.000 abstract 1
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000004626 essential fatty acids Nutrition 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Cosmetics (AREA)
- Optical Recording Or Reproduction (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939300125A GB9300125D0 (en) | 1993-01-06 | 1993-01-06 | Compositions containing esters of unsaturated fatty acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY110765A true MY110765A (en) | 1999-03-31 |
Family
ID=10728334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI94000009A MY110765A (en) | 1993-01-06 | 1994-01-04 | Compositions containing cholesteryl esters of unsaturated fatty acids |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5604216A (OSRAM) |
| EP (1) | EP0606012B1 (OSRAM) |
| JP (1) | JPH06234644A (OSRAM) |
| KR (1) | KR940018088A (OSRAM) |
| CN (1) | CN1096197A (OSRAM) |
| AT (1) | ATE168267T1 (OSRAM) |
| AU (1) | AU673555B2 (OSRAM) |
| CA (1) | CA2112824A1 (OSRAM) |
| DE (1) | DE69319710T2 (OSRAM) |
| DK (1) | DK0606012T3 (OSRAM) |
| ES (1) | ES2119871T3 (OSRAM) |
| GB (1) | GB9300125D0 (OSRAM) |
| MY (1) | MY110765A (OSRAM) |
| NO (1) | NO940035D0 (OSRAM) |
| NZ (1) | NZ250583A (OSRAM) |
| RU (1) | RU2142468C1 (OSRAM) |
| ZA (1) | ZA9425B (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107499A (en) * | 1988-02-26 | 2000-08-22 | Neuromedica, Inc. | Dopamine analog amide |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
| US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
| US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
| US7141266B2 (en) * | 1998-05-21 | 2006-11-28 | Beech-Nut Nutrition Corporation | Baby-food compositions enhancing visual acuity and methods therefor |
| US6579551B1 (en) | 1998-05-21 | 2003-06-17 | Beech-Nut Nutrition Corporation | Baby-food compositions containing egg yolk and methods therefor |
| US7413759B2 (en) * | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
| US6149964A (en) * | 1998-05-21 | 2000-11-21 | Beech-Nut Nutrition Corporation | Egg yolk-containing baby food compositions and methods therefor |
| NZ333817A (en) * | 1998-08-25 | 2000-09-29 | Mcneil Ppc Inc | Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels |
| US5892068A (en) * | 1998-08-25 | 1999-04-06 | Mcneil-Ppc, Inc. | Preparation of sterol and stanol-esters |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| AU2006201772B2 (en) * | 1999-01-27 | 2010-02-04 | Amarin Neuroscience Limited | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| AU775774C (en) * | 1999-04-15 | 2005-05-19 | Kaneka Corporation | Peroxisome proliferator-activated receptor agonist |
| JP2000355538A (ja) * | 1999-04-15 | 2000-12-26 | Kanegafuchi Chem Ind Co Ltd | ペルオキシゾーム活性化剤応答性受容体アゴニスト |
| US6998501B1 (en) * | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
| EP1211955A1 (en) * | 1999-08-30 | 2002-06-12 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| US20030206958A1 (en) * | 2000-12-22 | 2003-11-06 | Cattaneo Maurizio V. | Chitosan biopolymer for the topical delivery of active agents |
| ATE384518T1 (de) * | 2000-01-31 | 2008-02-15 | Haerting S A | Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels |
| KR20010091499A (ko) * | 2000-03-16 | 2001-10-23 | 김용범 | 레이저 그래픽 디스플레이 장치 |
| JP4594489B2 (ja) * | 2000-03-31 | 2010-12-08 | 備前化成株式会社 | 特異的殺癌細胞剤及びこれを配合してなる組成物 |
| EP1427407A4 (en) | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | FAT AMIN DRUG CONJUGATES |
| ES2387562T3 (es) * | 2001-03-23 | 2012-09-26 | Luitpold Pharmaceuticals, Inc. | Conjugados alcohol graso-medicamento |
| JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| DE10154221A1 (de) * | 2001-11-07 | 2003-05-15 | Max Delbrueck Centrum | Mittel zur Behandlung von Läsionen des Nervensystems |
| US20050123500A1 (en) * | 2003-01-31 | 2005-06-09 | The Procter & Gamble Company | Means for improving the appearance of mammalian hair and nails |
| WO2004068970A2 (en) * | 2003-01-31 | 2004-08-19 | The Procter & Gamble Company | Means for improving the appearance of mammalian keratinous tissue |
| DE602004019063D1 (de) * | 2003-04-02 | 2009-03-05 | Us Gov Health & Human Serv | Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi |
| CA2529735C (en) * | 2003-06-20 | 2012-07-10 | Mochida Pharmaceutical Co., Ltd. | Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities |
| CA2436650A1 (en) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses |
| WO2005107710A2 (en) * | 2004-05-06 | 2005-11-17 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
| US20060141046A1 (en) * | 2004-05-06 | 2006-06-29 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
| MX336435B (es) * | 2005-07-08 | 2016-01-19 | Dsm Ip Assets Bv | Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia. |
| US20080110624A1 (en) * | 2005-07-15 | 2008-05-15 | Halliburton Energy Services, Inc. | Methods for controlling water and particulate production in subterranean wells |
| ITMI20052377A1 (it) * | 2005-12-13 | 2007-06-14 | Anna Petroni | Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga |
| FR2902659A1 (fr) * | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
| AU2009288066B2 (en) | 2008-09-02 | 2015-12-24 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| PT3037089T (pt) | 2009-02-10 | 2020-03-04 | Amarin Pharmaceuticals Ie Ltd | Ester etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia |
| DK3278665T3 (da) | 2009-04-29 | 2020-11-30 | Amarin Pharmaceuticals Ie Ltd | Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf |
| NZ807894A (en) | 2009-04-29 | 2025-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CA3129996C (en) | 2009-06-15 | 2025-09-02 | Amarin Pharmaceuticals Ireland Limited | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| US8889840B2 (en) * | 2009-10-29 | 2014-11-18 | Industry-Academic Cooperation Foundation, Yonsei University | Vascular leakage inhibitor |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
| EP3692981B1 (en) * | 2012-10-11 | 2022-05-04 | Chem-Cure Associates LLC | Topical composition for use in the treatment of psoriasis |
| US9717741B2 (en) | 2012-10-11 | 2017-08-01 | Anaplasi Pharmaceuticals Llc | Method and compositions for treating psoriasis |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| JP6224203B2 (ja) * | 2016-12-08 | 2017-11-01 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するための組成物 |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| JP6491293B2 (ja) * | 2017-10-04 | 2019-03-27 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| JP6728425B2 (ja) * | 2019-02-28 | 2020-07-22 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するためのクリーム、ローション、又はゲルの組成物 |
| WO2021097120A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4442037A (en) * | 1981-03-13 | 1984-04-10 | Yoshio Arakawa | Water-soluble cholesterol derivative |
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| SU1456442A1 (ru) * | 1987-04-03 | 1989-02-07 | Житомирский Государственный Педагогический Институт Им.И.Франко | (Холестерилоксикарбонилметил)трифенилфосфонийхлорид в качестве полупродукта в синтезе холестериловых эфиров непредельных карбоновых кислот |
-
1993
- 1993-01-06 GB GB939300125A patent/GB9300125D0/en active Pending
- 1993-12-23 NZ NZ250583A patent/NZ250583A/xx unknown
- 1993-12-29 AT AT93310599T patent/ATE168267T1/de not_active IP Right Cessation
- 1993-12-29 EP EP93310599A patent/EP0606012B1/en not_active Expired - Lifetime
- 1993-12-29 ES ES93310599T patent/ES2119871T3/es not_active Expired - Lifetime
- 1993-12-29 DK DK93310599T patent/DK0606012T3/da active
- 1993-12-29 DE DE69319710T patent/DE69319710T2/de not_active Expired - Fee Related
- 1993-12-30 AU AU52763/93A patent/AU673555B2/en not_active Ceased
-
1994
- 1994-01-04 ZA ZA9425A patent/ZA9425B/xx unknown
- 1994-01-04 MY MYPI94000009A patent/MY110765A/en unknown
- 1994-01-05 NO NO940035A patent/NO940035D0/no unknown
- 1994-01-05 CA CA002112824A patent/CA2112824A1/en not_active Abandoned
- 1994-01-05 RU RU94000061A patent/RU2142468C1/ru active
- 1994-01-06 CN CN94100242A patent/CN1096197A/zh active Pending
- 1994-01-06 JP JP6000338A patent/JPH06234644A/ja active Pending
- 1994-01-06 US US08/178,553 patent/US5604216A/en not_active Expired - Fee Related
- 1994-01-06 KR KR1019940000159A patent/KR940018088A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69319710T2 (de) | 1999-03-11 |
| ATE168267T1 (de) | 1998-08-15 |
| GB9300125D0 (en) | 1993-03-03 |
| RU2142468C1 (ru) | 1999-12-10 |
| CN1096197A (zh) | 1994-12-14 |
| EP0606012B1 (en) | 1998-07-15 |
| AU673555B2 (en) | 1996-11-14 |
| AU5276393A (en) | 1994-07-14 |
| EP0606012A1 (en) | 1994-07-13 |
| US5604216A (en) | 1997-02-18 |
| CA2112824A1 (en) | 1994-07-07 |
| DE69319710D1 (de) | 1998-08-20 |
| NZ250583A (en) | 1997-08-22 |
| ZA9425B (en) | 1994-08-19 |
| DK0606012T3 (da) | 1999-04-19 |
| JPH06234644A (ja) | 1994-08-23 |
| NO940035D0 (no) | 1994-01-05 |
| KR940018088A (ko) | 1994-08-16 |
| NO940035L (OSRAM) | 1994-07-07 |
| ES2119871T3 (es) | 1998-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY110765A (en) | Compositions containing cholesteryl esters of unsaturated fatty acids | |
| AU671329B2 (en) | Formulations containing unsaturated fatty acids | |
| PH29944A (en) | Washing composition constaining fatty acid esters | |
| NO940277L (no) | Triglycerider og blandinger av slike | |
| CA2218702A1 (en) | Fatty acid esters as bioactive compounds | |
| AU4800393A (en) | Liquid detergent compositions containing protease and certain beta -aminoalkylboronic acids and esters | |
| AU6821294A (en) | Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto | |
| IL103932A (en) | Fatty acid and pharmaceutical compositions containing them | |
| AU6912994A (en) | Catalyst and process for using same for the preparation of unsaturated carboxylic acid esters | |
| AU1575783A (en) | Skin treatment compositions containing a fatty acid or ester | |
| AU3795193A (en) | Fluid compositions containing polyhydroxy fatty acid amides | |
| AU5334894A (en) | Compositions of fatty acid esters of hexitans | |
| AU5714294A (en) | Process for the preparation of esters of 2-cyanoacrylic acid and use of the esters so prepared as adhesives | |
| EP0356726A3 (en) | Fuel compositions containing esters from polycarboxylic acids and long chain alcohols | |
| AU7300294A (en) | Sulfonation of fatty acid esters | |
| CA2108707A1 (en) | Esters of l-carnitine and alkanoyl l-carnitines with glycolic acid or esters thereof and pharmaceutical compositions containing same for treating dermatoses | |
| AU1821888A (en) | Treatment or prevention of memory loss using essential fatty acid compositions | |
| CA2197838A1 (en) | Mouthfeel and lubricity enhancing composition | |
| AU563273B2 (en) | Composition containing an essential fatty acid and niacin and/or a bile salt binder | |
| AU3674589A (en) | Skin- or hair-care compositions containing silica and carboxylic acid esters | |
| AU571090B2 (en) | 3, 17beta-estriol diesters | |
| AU5464094A (en) | Cosmetic composition containing succinic acid esters | |
| AU3051095A (en) | Liquid compositions containing complex carboxylic esters | |
| AU6724890A (en) | Method for the preparation of fat mixtures comprising eicosapentaenoate ester from worms of family lumbricidae and, optionally fatty acid mixtures comprising eicosapentaenoic acid therefrom | |
| AU3557893A (en) | Dispersions of polymer additives in fatty acid esters |